Objective. The comparative mortality figure (CMF) is the expected number of deaths in the standard population compared with those observed. We assessed state-based CMFs for people with HIV infection to allow standardized assessment of mortality in all states.
State mortality rates for people infected with human immunodeficiency virus (HIV) vary greatly, and comparability among states will benefit from enhanced standardization. The 2010 death rate of HIV-infected people aged $13 years in the United States was 7.5 per 100,000 population, with state rates ranging broadly from 0.4 per 100,000 population in Maine to 38.8 per 100,000 population in the District of Columbia (DC). 1 Similarly, in the same age group of people diagnosed with HIV infection, those with stage 3 infection (i.e., acquired immunodeficiency syndrome [AIDS]) 2 had a death rate of 6.1 per 100,000 population in 2010, with state rates also ranging broadly from 0.3 per 100,000 population in Maine to 33.7 per 100,000 population in DC. The large disparity among state death rates for people with HIV infection, and the disproportionate impact on some racial/ethnic, risk factor, and age groups, 3 indicates a need for standardization of each state rate to a fixed population to enhance comparability. This study provides those results.
Testing for HIV infection is recommended by the U.S. Preventive Services Task Force for all adolescents and adults aged 15-65 years and for all pregnant women 4 to increase early detection, facilitate treatment, reduce transmission, and reduce mortality. 5, 6 While testing with rapid tests, in-home, and at other nonmedical facilities has increased the number of people with HIV infection who know their status, it is estimated that in 2010, one in six people with HIV infection did not know they were infected. 7 In addition, despite implementation of a variety of prevention strategies, 8 increased testing, linkageto-care activities, and improved HIV infection treatments aimed at viral load suppression have resulted in increased prevalence of people living with HIV infection. The 2013 Presidential Continuum of Care Initiative recommends further enhancements to identify and address gaps in care along the continuum, beginning with diagnosis and moving though sequential stages for linkage to care, retention in care, and antiretroviral treatment (ART) utilization, resulting in viral suppression. 9 Comparisons of state mortality, the ultimate indicator of success along the continuum of care, can inform HIV infection testing and care initiatives, and evaluate the impact of linkage to and retention-in-care activities. However, the method selected for analysis can significantly affect the results. 10 Standardized methods for presenting state death rates are necessary to ensure comparability of state mortality.
Numerous methodologies for assessing standardized mortality rates have been documented. 10, 11 The standardized mortality ratio for indirect standardiza-tion is commonly reported, although the comparative mortality figure (CMF) (or comparative mortality ratio [CMR] derived from CMFs) for direct standardization is recommended for geographic comparisons among heterogeneous populations. [12] [13] [14] While the CMF has been used for mortality studies of chronic disease and disability, [15] [16] [17] [18] [19] it has not previously been used to compare state-level CMFs for people diagnosed with HIV infection using data from a national HIV surveillance system.
METHODS
The Centers for Disease Control and Prevention's (CDC's) population-based National HIV Surveillance System (NHSS) captures and links multiple source documents (e.g., HIV case report forms, laboratory and physician reports, and death certificates) for each person known to be infected with HIV to populate demographic, risk factor, clinical care, laboratory result, and mortality data elements. Reporting of data on people diagnosed with HIV infection is mandatory in all states, DC, and U.S. dependent areas, and the jurisdictions send the data to CDC without personal identifying information. State and local linkage of NHSS to vital statistics death certificates, the Social Security Death Master File (SSDMF), 20 and the National Death Index (NDI) 21 is required no less than annually to identify with HIV infection those who are deceased [22] [23] [24] from any cause, not just deaths resulting from HIV infection. Our analysis allowed for 24 months of reporting delay to identify deaths in NHSS.
For this analysis, we included people diagnosed with HIV infection who met the CDC HIV infection case definition; 25 were diagnosed with HIV infection at any stage from January 1, 2001, to December 31, 2010; and were alive on December 31, 2009 (defined as the absence of a death certificate or other confirmation of death in the surveillance system). Because name-based HIV reporting was implemented over time in different jurisdictions, data were not available for all areas for the analysis time period. We included data for those who were residents at the earliest date of HIV or AIDS diagnosis of one of 33 26 All data reported to the national surveillance system as of December 31, 2012, were used in the analysis.
Stage of disease at diagnosis was defined as the absence of an AIDS diagnosis within three months of an HIV diagnosis (hereinafter referred to as "early stage") or the presence of a confirmed AIDS diagnosis within three months of an HIV diagnosis (hereinafter referred to as "late stage").
Data were adjusted for case reporting delay, death reporting delay, and age group. No adjustment was made for underreporting. We calculated age categories using the age in years on December 31, 2009 , for those in the study population who were still alive and age at death for those who died in 2010. We calculated CMFs using the following formulas: CMF 5 Or,
Expected deaths (in standard population)
Observed deaths (in standard population)
where N i is the number of people in the standard population, D i is the number of deaths in the standard population, and n i and d i are the number of people and number of deaths in the study population, respectively. 13 Results are presented by stage of disease at diagnosis in aggregate and by state for the 33 states with namebased reporting since 2001. The health status of a place is judged to be better when the CMR of that place is lower than other places. 12 We calculated CMRs using the following formula:
Subsequent tables present results for all 50 states and DC and include the CMFs for those diagnosed with AIDS from 2001 to 2010 regardless of date of first HIV infection diagnosis. These tables provide comparative data for all states including those that did not have HIV infection name-based reporting until after 2001 and for which only AIDS information was available. Table 1 , there were 6,564 deaths of those initially diagnosed with early-or late-stage HIV infection from 2001 to 2010 who were alive on December 31, 2009, but died during 2010 in the 33 states included in this analysis (4,765 males and 1,799 females). The CMFs for males and females initially diagnosed during early-stage HIV infection were similar (2.8 and 2.7, respectively). As expected, those initially diagnosed during the late stage had higher mortality than those diagnosed at an early stage, and mortality was higher for males (4.6) than for females ( Table 2) .
RESULTS

As shown in
Excluding the six potentially unstable CMFs in states with fewer than 12 deaths, early-stage diagnosis CMFs by state ranged from 0.9 in Wisconsin to more than four times that (4.2 each) in Alabama and Arkansas, CMFs for late stage varied from 1.9 in Iowa to nearly five times that (9.7) in Nebraska, and total (all stages) ranged from 1.4 in Wisconsin to 4.6 in Alabama. The mean difference between early-and late-stage CMFs was 1.9, excluding the six low death count states, and 2.2 for all 33 states ( (Table 3) , which was identical to the CMF (Table 4 ).
DISCUSSION
The CMFs showed substantial variation in mortality among states even after adjusting for age and reporting delay. Differences in mortality by state of residence among those diagnosed with HIV may be due to differences in additional population characteristics (e.g., sex), jurisdictional capacity to deliver care, individual ability to access care, and socioeconomic factors. The percentage of those diagnosed with advanced-stage HIV disease varied by state, and survival among those with advanced disease was lower than among those diagnosed with early-stage disease. 2, 27 Little information exists on any differences among states in the prescription or use of ART. However, geographic differences exist in prompt linkage to care after HIV diagnosis and retention in HIV care and viral suppression among those living with HIV. 28 The percentage of people who did not have health insurance coverage also varied by state. 29 Early diagnosis of HIV, prompt linkage to and sustained HIV care, and ART prescriptions are the necessary steps in the continuum of care to ultimately achieve viral suppression for optimal health. Yet, about one-third of those with HIV are diagnosed with latestage disease annually, 27 and many people with HIV are not in continuous care, on ART, or have a suppressed viral load, 30 the result of which is often death. Late diagnosis, however, is unlikely to explain the disparity in death rates between black/African Americans and white people, as there was little difference in the percentage classified with late stage at diagnosis between these groups. 27 The results correspond to earlier findings of significantly higher case fatality (i.e., deaths among those living with HIV) among black/ African Americans compared with the non-Hispanic, non-black/African American population living with HIV, 2,10 and life expectancy has been found to be lower in black/African American and Hispanic or Latino males than in white males. 31 The results may possibly be due to differences in care and treatment due to community capacity to provide care and individual factors. The percentage of black/African Americans who are linked to care within three months of diagnosis, who are in continuous care, and who have a suppressed viral load is lower than that of white people. 32, 33 Black/ African Americans are less likely than white people to have health insurance (21% vs. 16%, respectively) 34 and may experience other socioeconomic situations, such as poverty and lack of transportation, that hinder accessing care. Additional factors that may lead to differences in accessing and remaining in HIV care among states as well as between subpopulations within states may include the distribution of groups with specific risk factors, lack of social support, unstable housing, lack of transportation, lower education, poverty, unemployment, racism, and stigma. [35] [36] [37] Bridging these barriers may help states with higher mortality reduce deaths.
Limitations
This study was subject to a number of limitations related primarily to case and death ascertainment. First, not all of those with HIV infection were identified and entered in the NHSS, including many who were unaware of their HIV infection status (i.e., not yet diagnosed). However, recent capture-recapture analyses of completeness of case reporting indicate the vast majority of states identify more than 95% of their estimated number of new cases annually. 38 It is not possible to know how many cases are undiagnosed in a given year although, as part of the death ascertainment process, death certificates with an indication of HIV are provided to the NHSS to ensure they were previously reported. Second, those reported to the NHSS are assumed to be alive unless their death has been reported to CDC. Death ascertainment standards require that states match all vital statistics, SSDMF, and NDI death records to NHSS annually. However, at the time of this study, California (Los Angeles County) and Oregon had not completed that process for deaths occurring in 2010, likely resulting in an underestimate of their CMFs. 38 Third, eight states are currently prohibited by state law from linking NHSS data to the NDI, as doing so requires the sharing of personal identifying information outside the state health department. These states may not obtain information for a person diagnosed with HIV infection in the state who may have died somewhere else. NDI data are also used to capture cause of death codes in addition to new deaths. Fourth, this study included deaths by all causes, not just those resulting from HIV infection; thus, they cannot be interpreted as mortality due strictly to HIV infection. While the death rate of people with HIV infection (or AIDS) is greater than the rate of people of similar ages without HIV infection (or AIDS) or without access to ART, HIV infection is almost universally fatal. Lastly, reported numbers of ,12 in all tables should be interpreted with caution because the numbers have underlying relative standard errors .30% and are considered unreliable.
CONCLUSION
Death rates from all causes among those with HIV infection varied by state of residence at HIV diagnosis. People diagnosed with advanced disease and black/ African Americans had a higher death rate than people who were diagnosed early or who were white, respectively. The 2010 rate ratio of deaths of black to white people with HIV infection (8.2) was 10 times as high as the rate ratio of black to white people without HIV infection (0.8). 26 In addition, approximately 42% of states exceeded the national CMF for both HIV infection and AIDS. It is critical that testing efforts continue to expand and become part of routine medical care for early diagnosis. Expansion of jurisdictional capacity and individual access to health-care services and medical insurance coverage may help ensure that those diagnosed with HIV infection enter and remain in care to benefit from advances in ART. Novel approaches to improve retention in HIV care and reengage people who have not been in continuous care are needed. Providing affordable care to all those diagnosed with HIV infection according to the updated HIV treatment guidelines 39 may help reduce geographic and demographic disparities in mortality. Finally, additional studies comparing high and low mortality states with similar risk group distribution, population characteristics, health-care access, socioeconomic indicators, and similar factors will help inform future prevention and treatment strategies.
